eduKate Learning Manual
Science | Veterinary World
Define the Morphological Differential → Select a Marker Panel → Validate Controls → Account for Fixation and Antigen Retrieval → Read Staining Pattern and Distribution → Compare With Tissue Architecture → Update the Diagnosis

Veterinary Immunohistochemistry

Why a Positive Tumour Marker Does Not Identify Cell Origin by Itself

Wait, What? A Brown-Stained Tumour Cell Can Be Truly Positive for a Marker and Still Not Tell You the Whole Identity of the Tumour

Immunohistochemistry—usually shortened to IHC—uses antibodies to reveal selected proteins inside preserved tissue sections. It is one of the most powerful tools in veterinary diagnostic pathology because it lets a pathologist ask whether suspicious cells express proteins associated with epithelial, mesenchymal, lymphoid, melanocytic, endocrine or other lineages.

But no antibody knows the diagnosis.

Many markers are sensitive rather than perfectly specific. Some tumours lose expected proteins. Some express unexpected ones. Fixation can destroy antigen recognition. Background staining can imitate true signal. A marker validated in one species or tissue may behave differently in another.

positive stain = antigen detected under that assay; positive stain ≠ tumour origin proven by itself.

The Scientific Job

This page owns one Veterinary World job:

How should veterinary pathologists interpret tumour immunohistochemistry using marker panels, tissue controls, staining pattern, fixation context and morphology without treating one positive antibody as definitive proof of cell lineage or tumour origin?

Veterinary Cytology vs Histopathology retains the distinction between cell-level and tissue-architecture evidence. Veterinary Oncology retains tumour behaviour and staging. Veterinary Flow Cytometry retains live-cell immunophenotyping. This page owns the narrower interpretation of protein markers within tissue architecture.

Quick Answer

IHC is most reliable when used as a panel chosen from a morphological differential, not as a fishing expedition. Interpretation requires validated antibodies, positive and negative controls, attention to fixation and antigen retrieval, correct cellular localisation of staining, and comparison with tissue architecture. A marker can support a lineage strongly without being absolutely specific.

AAVLD guidelines emphasise validation, antibody selection, fixation, antigen retrieval, tissue and reagent controls, interpretation and quality assurance. The 2025 Oncology-Pathology Working Group consensus on canine nodal lymphoma places histopathology plus immunohistochemistry at the centre of complete nodal lymphoma classification, illustrating how IHC becomes strongest when embedded in preserved architecture rather than interpreted as isolated marker positivity.

Explore AAVLD — Suggested IHC Guidelines for Veterinary Diagnostic Laboratories →

Explore 2025 OPWG Consensus — Canine Nodal Lymphoma Classification →

Primary Entry — Morphology Comes Before the Marker Panel

A pathologist first asks what the tumour looks like on routine histology: round-cell, epithelial, spindle-cell, melanocytic, endocrine, histiocytic or mixed? Where is it located? How does it invade? What structures does it form?

Those observations generate a differential diagnosis. The marker panel is then selected to separate plausible possibilities.

morphology narrows the question; IHC tests the remaining identities.

Part 1 — Sensitivity and Specificity Are Different Properties

A sensitive marker is expressed by many tumours of the target lineage. A specific marker is rarely expressed by unrelated tumours.

Some markers are excellent screens because they are sensitive but not perfectly specific. Others are highly specific but miss a substantial fraction of true tumours. Good panels balance these properties rather than demanding impossible perfection from one antibody.

Part 2 — Cellular Location of the Stain Matters

A marker expected in the nucleus should not be interpreted the same way if staining appears only as vague cytoplasmic haze. A membrane marker should show a pattern consistent with membrane localisation.

Correct subcellular distribution is part of the evidence that the stain is biologically meaningful rather than background artefact.

Part 3 — Positive Controls Show That the Assay Could Work

A known positive control tissue demonstrates that the antibody and detection chemistry performed as expected. Internal positive controls—normal cells within the patient section known to express the antigen—can be even more valuable because they experienced the same fixation and processing as the tumour.

If the control fails, a negative tumour stain is uninterpretable.

negative tumour + failed control ≠ true negative.

Part 4 — Negative Controls Protect Against Background Signal

Non-specific binding, endogenous enzyme activity, pigments and detection chemistry can create signal unrelated to the target antigen.

Appropriate negative controls help determine whether apparent positivity reflects genuine antibody binding or a background process.

Part 5 — Fixation Can Erase Antigen Without Erasing the Tumour

Formalin preserves tissue by cross-linking proteins. That preserves architecture beautifully but can mask antibody-binding sites.

Over-fixation, under-fixation, delayed fixation and decalcification can alter antigen availability. A tumour that is biologically positive can therefore appear weak or negative because processing changed the epitope.

Secondary Deepening — Antigen Retrieval Is Controlled Reversal of Masking

Heat-induced or enzymatic antigen retrieval can expose epitopes hidden by fixation. But retrieval conditions must be validated for the specific antibody, species and tissue.

Too little retrieval produces weak staining. Too much can damage morphology or increase background. This is why method validation belongs inside diagnostic interpretation rather than outside it.

Part 6 — Marker Panels Work by Logical Intersection

Suppose a poorly differentiated tumour is cytokeratin-positive and vimentin-negative. That pattern supports epithelial differentiation more strongly than cytokeratin positivity alone if the markers were properly validated and morphology agrees.

Similarly, lymphoid lineage is often strengthened by combining B-cell and T-cell markers rather than relying on a single antigen.

panel pattern > isolated stain.

Part 7 — Aberrant Expression Does Occur

Neoplastic cells can lose proteins expected for their lineage or express markers normally associated with other cells. Poorly differentiated tumours are particularly prone to unusual phenotypes.

This is why an unexpected positive should trigger reassessment rather than automatic reclassification. The pathologist asks whether the stain is specific, whether localisation is correct, whether controls worked and whether a broader panel resolves the conflict.

Part 8 — Species Validation Cannot Be Assumed

An antibody developed for human pathology may or may not recognise the corresponding canine or feline antigen reliably. Even when it cross-reacts, staining pattern and sensitivity can differ.

The AAVLD guidance therefore emphasises assay validation in the intended species and tissue context rather than assuming that commercial availability equals veterinary validity.

JC Deepening — IHC Is Bayesian Pattern Matching Inside Tissue

Before staining, morphology creates a set of plausible tumour identities. Each marker result shifts those probabilities.

A highly specific positive marker can sharply raise one diagnosis. A sensitive but non-specific marker raises it less. A negative marker is informative only if sensitivity is high and the control proves the antigen could have been detected.

pre-test morphology × marker performance × staining pattern × controls = post-test diagnostic confidence.

Part 9 — Ki-67 Shows Why Prognostic Markers Need Their Own Validation

Some IHC markers are used not primarily to identify lineage but to estimate proliferation or receptor status. Ki-67 is a classic proliferation marker.

But cut-offs, counting methods, tumour type and specimen quality influence prognostic meaning. A high Ki-67 percentage should not be transferred between unrelated tumour types as though one universal threshold exists.

Part 10 — Canine Mammary Tumours Illustrate the Need for Standardised Scoring

Consensus work on canine mammary tumours has addressed epithelial and myoepithelial markers, HER2 and hormone-receptor assessment precisely because different antibodies, scoring methods and cut-offs make studies difficult to compare.

Explore Consensus Guidelines — IHC Markers in Canine Mammary Tumours →

Part 11 — IHC and Flow Cytometry Preserve Different Information

Flow cytometry measures many live cells rapidly and can quantify marker combinations across populations. IHC measures fewer markers per section but preserves spatial relationships and tissue architecture.

For lymphoma, the 2025 consensus considers both flow cytometry and IHC reliable immunophenotyping methods, while histopathology with IHC remains required for complete nodal classification.

Part 12 — A Negative Panel Can Mean “Unknown”, Not “Nothing”

Some poorly differentiated neoplasms remain unclassified after extensive panels. That can reflect true biological loss of lineage markers, limited antibody availability or a tumour type not represented in the chosen panel.

Scientific honesty sometimes ends with “poorly differentiated neoplasm, lineage unresolved” rather than a falsely precise label.

How Do We Know?

Veterinary IHC practice is supported by laboratory standardisation guidelines, tumour-specific consensus documents and comparative oncology/pathology working groups. These sources consistently emphasise validation, controls, fixation, appropriate marker panels and interpretation in morphology rather than single-marker diagnosis.

Observation vs Inference

• Observation: a poorly differentiated tumour shows strong membranous staining for a validated epithelial marker and no staining for a validated mesenchymal marker.
• Inference: epithelial differentiation is strongly supported if controls and morphology agree.
• Observation: one tumour cell cluster shows weak diffuse cytoplasmic staining for a marker expected in nuclei.
• Inference: non-specific or aberrant staining should be considered before changing diagnosis.
• Observation: tumour is negative but internal normal tissue is also negative.
• Inference: assay failure or antigen loss from processing makes the negative tumour result unreliable.
• Observation: a lineage panel is internally contradictory.
• Inference: aberrant phenotype, mixed tumour or technical factors need investigation.

Evidence Boundaries

• positive marker ≠ tumour origin proven alone.
• negative marker ≠ lineage excluded if sensitivity or control is weak.
• human-validated antibody ≠ veterinary-validated assay automatically.
• staining intensity ≠ prognosis without validated scoring.
• one marker ≠ panel.
• aberrant expression ≠ impossible biology.
• IHC ≠ molecular clonality.
• pathology classification ≠ treatment instruction.

Common Misconceptions

Misconception	Better model
The marker is positive, so the tumour is definitely that lineage.	Marker specificity, pattern, controls and morphology determine how much weight positivity deserves.
A negative stain rules the tumour out.	Only a validated, sensitive assay with working controls makes a negative result strongly exclusionary.
More antibodies always mean more certainty.	A logically chosen panel is better than indiscriminate staining that generates contradictions.
IHC is objective because the stain is visible.	Scoring, localisation, thresholds and technical quality still require expert interpretation.

Unfamiliar Transfer

Dog A has a spindle-cell tumour positive for one broad mesenchymal marker. Dog B has a round-cell tumour with a coherent B-cell IHC panel. Cat C has an undifferentiated tumour with conflicting epithelial and mesenchymal markers. Dog D has a negative stain but failed internal control.

A strong learner does not count positives. The learner asks what each marker can and cannot exclude, whether the staining is in the right place, and whether the tissue architecture tells the same story.

Checkpoint Questions

1. What does immunohistochemistry detect?
2. Why should morphology come before marker selection?
3. What is the difference between sensitivity and specificity?
4. Why does subcellular stain location matter?
5. What does a positive control prove?
6. Why can fixation cause false-negative staining?
7. Why is a panel stronger than one marker?
8. Why must antibodies be validated in the target species?
9. How is IHC different from flow cytometry?
10. When is an unresolved diagnosis scientifically preferable?

Answer key

1. Selected protein antigens within preserved tissue sections.
2. It defines plausible diagnoses and makes marker use targeted.
3. Sensitivity captures many true cases; specificity avoids unrelated positives.
4. True biological expression usually has an expected nuclear, membranous or cytoplasmic distribution.
5. That the assay chemistry and antibody can produce expected staining.
6. Cross-linking or processing can mask epitopes.
7. Independent markers constrain lineage more reliably.
8. Cross-reactivity and performance can differ across species and tissues.
9. IHC preserves architecture; flow cytometry measures many live cells and marker combinations.
10. When available evidence cannot support a narrower label without overclaiming.

Edge Science — Can Multiplex Spatial Pathology Replace One-Stain-at-a-Time Panels?

Multiplex immunofluorescence, digital pathology and spatial transcriptomics can measure many markers while preserving tissue location. These tools may reveal tumour-cell identity, immune microenvironment and signalling state simultaneously.

The challenge remains validation. High-dimensional tissue maps are only as trustworthy as antibody specificity, segmentation, species annotation and biological interpretation. More channels do not remove the need for controls.

Veterinary World Direction Graph

Veterinary immunohistochemistry → tissue morphology → differential diagnoses → validated marker panel → fixation/retrieval audit → positive/negative controls → cellular staining pattern → architecture integration → diagnostic confidence → additional molecular testing if unresolved.

Research Sources and Further Reading

• AAVLD Suggested Guidelines for Immunohistochemical Techniques in Veterinary Diagnostic Laboratories
• 2025 OPWG Consensus — Canine Nodal Lymphoma Diagnosis and Classification
• Consensus Guidelines on IHC Markers in Canine Mammary Tumours
• OPWG Consensus — Use and Future Directions of Immunocytochemistry in Veterinary Medicine

Educational boundary: Tumour classification requires veterinary pathology and clinical oncology expertise. This manual explains marker interpretation only and does not provide chemotherapy selection, prognosis for an individual animal or treatment recommendations.

Teaching Guide for Parents, Tutors and Teachers

For the people who teach because somebody depends on them.

Imagine identifying a person from clothing. A lab coat strongly suggests a scientific or medical role, but it does not prove the wearer’s profession. Add a hospital badge, department, workplace and job record, and identity becomes much stronger. IHC works the same way.

start with structure → choose discriminating markers → verify controls → inspect where the stain appears → combine the panel → keep unresolved cases unresolved when evidence is insufficient.

The mastery target is a learner who understands that a biomarker contributes evidence to identity—it does not magically contain identity inside itself.